Table 1.

Geometric mean titer and geometric mean fold rise from pre- to post-vaccination of varicella zoster virus antibody titers (measured by gpELISA ) in the per-protocol set (primary analysis) and the full analysis set (supportive analysis) after vaccination with ZOSTAVAX at minimum-release specification approaching expiry potency

	GMT, gpELISA units/mL [95% CI]		GMFR* [95% CI]
	Pre-vaccination	28–35 d after ZOSTAVAX
Per-protocol set
All (N = 92)	215.8 [178.1, 261.4]	674.0 [565.4, 803.5]	3.1 [2.6, 3.8]
50–59 y (n = 48)	224.6 [166.5, 302.9]	868.1 [692.8, 1087.7]	3.9 [2.9, 5.1]
≥60 y (n = 44)	206.6 [161.7, 263.9]	511.4 [395.5, 661.2]	2.5 [1.9, 3.2]
Full-analysis set
All (N = 96)	218.4 [181.0, 263.5]	700.1 [588.7, 832.5]	3.2 [2.6, 3.9]
50–59 y (n = 50)	228.6 [170.0, 307.3]	891.1 [713.8, 1112.3]	3.9 [3.0, 5.1]
≥60 y (n = 46)	207.8 [164.3, 262.8]	538.6 [416.9, 695.9]	2.6 [2.0, 3.4]

^*The VZV antibody response was defined as acceptable if the lower limit of the 95% CI of the GMFR was >1.4. CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; gpELISA, glycoprotein enzyme-linked immunosorbent assay; VZV, varicella zoster virus.